Gastrointestinal Medical Oncology at MD Anderson Cancer Center
Oncology
Dr. Edmund S. Kopetz, MD
|
|
Give Review
Edmund Kopetz is an expert in the field of Oncology. He researched medicine at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a one of the best medicals schools. Johns Hopkins University School of Medicine is ranked 3 in research and 29 in primary care medicine Edmund S. Kopetz is a published physician. He has 42 publications published. The most current publication "RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases." He accepts Medicare payments and is registered with Medicare.gov.
Publications
- The consensus molecular subtypes of colorectal Cancer.
- 5-Fluorouracil resistant colon Cancer cells are addicted to OXPHOS to survive and enhance stem-like traits.
- Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors.
- The clinical and biological significance of MIR-224 expression in colorectal Cancer metastasis.
- Expanded RAS: Refining the Patient Population.
- Blood-Based Tests for Colorectal Cancer Screening: Do They Threaten the Survival of the FIT Test?
- Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic Tumors.
- Genomic classifier ColoPrint predicts recurrence in stage II colorectal Cancer patients more accurately than clinical factors.
- Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes.
- The requirement for freshly isolated human colorectal Cancer (CRC) cells in isolating CRC stem cells.
- BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity.
- Association between KRAS mutation and lung metastasis in advanced colorectal Cancer.
- Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression.
- Significant Association of oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients.
- Is Complete Liver Resection Without Resection of Synchronous Lung Metastases Justified?
- Clinicopathologic Characteristics and Gene Expression Analyses of Non-KRAS 12/13, RAS-Mutated Metastatic Colorectal Cancer.
- Topoisomerase IIα in chromosome instability and personalized Cancer therapy.
- Therapeutic Silencing of KRAS using Systemically DeLivered siRNAs.
- RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of ColoRectal Liver Metastases.
- Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal Cancer.
- Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer.
- Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast Cancer.
- Convergence of Nanotechnology and Cancer Prevention: Are We There Yet?
- Return to intended oncologic treatment (RIOT): A novel metric for evaluating the quality of oncosurgical therapy for malignancy.
- Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target.
- Clinical biomarkers in colorectal Cancer.
- Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal Cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007.
- Platelets and Cancer: a casual or causal relationship: revisited.
- Combined Targeting of STAT3/NF-κB/COX-2/EP4 for Effective Management of Pancreatic Cancer.
- Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase 1 Trial.
- FXR Silencing in Human Colon Cancer by DNA methylation and KRAS Signaling.
- Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations.
- Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal Cancer who undergo resection after ...
- From multidisciplinary to personalized treatment of coloRectal liver metastases: 4 reasons to consider RAS.
- The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal Cancer.
- RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for ColoRectal Liver Metastases.
- Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of Disease-free survival after pr...
- Endothelin-1 as a target for therapeutic intervention in prostate Cancer.
- Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal Cancer.
- RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of ColoRectal Liver Metastases.
- Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral ColoRectal Liver Metastases.
Schools
Johns Hopkins Univ Sch Of Med
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Choice
- Cigna
- Commercial Insurance Company
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Old Surety Life Insurance CompanyMedicare MCR
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
University of Texas MD Anderson Cancer Center -
Duke University Hospital -
Johns Hopkins University School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1205920048 | |
| NPPES Provider LastName | KOPETZ | |
| NPPES Provider FirstName | EDMUND | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 194.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1205920048 |
| Last Name Of The Provider | KOPETZ |
| First Name Of The Provider | EDMUND |
| View All |
Similar Doctors
|
|
Dr. Charles Osborne, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathy Sam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Henry J. Conter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vassiliki A. Papadimitrakopoulou, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Paulo M. Hoff, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Teresa G. Hayes, MD |
|
|
Dr. Arlene O. Siefker-Radtke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria A. Scouros, MD
This Doctor is OpenDoctor Recommended.
|